4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, has today announced that David Norwood has purchased 10,000 ordinary shares in the Company as listed below. Following this transaction, Mr Norwood has a resulting interest in the ordinary shares of the Company as listed below.
|
Name |
Shares in 4D pharma plc before purchase |
% of total shares in issue |
Shares in 4D pharma plc after purchase |
% of total shares in issue |
|
|
David Norwood (Chairman) |
7,070,000 |
10.79% |
7,080,000 |
10.81% |
4D Pharma are pioneers in understanding and utilising the functionality of bacteria as a revolutionary new class of medicines – called live biotherapeutics.
The bacteria which colonise the human gastrointestinal tract – known as the gut microbiome – have emerged as one of the most promising targets in medicine. More than just aiding in the digestion of food and production of vitamins; they are important in the development and regulation of our immune system. The company are also forging an understanding of their role in the maintenance of our central nervous system.
